Welcome to our dedicated page for Edap Tms SEC filings (Ticker: EDAP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
EDAP TMS SA filings document a France-based medical-device issuer with Nasdaq-listed American depositary shares, each representing one ordinary share. Its current reports cover operating results for the HIFU business, Focal One robotic HIFU system sales and procedure trends, ESWL and Distribution revenue, investor presentation materials, and product regulatory updates such as FDA 510(k) clearances for Focal One enhancements.
The company’s SEC disclosures also record capital-structure and financing matters, including a European Investment Bank credit facility and related warrants to purchase ordinary shares. Governance filings address board composition, committee assignments, and shareholder-vote matters, while foreign-issuer reports provide formal disclosure around EDAP’s therapeutic ultrasound strategy, risk statements, and public-company reporting obligations.
EDAP TMS S.A. filed a Form 8-K to share that it is presenting at the Oppenheimer 36th Annual Healthcare MedTech & Services Conference, with its investor presentation furnished as an exhibit and webcast through the investor section of its website.
The presentation highlights EDAP as a global leader in therapeutic ultrasound, focused on prostate cancer and other benign diseases. It emphasizes the large market of about 1.5 million new prostate cancer cases per year, the role of its Focal One robotic HIFU system as an organ-preserving treatment, and strong supporting clinical evidence versus surgery and radiation.
EDAP also showcases favorable U.S. Medicare reimbursement for HIFU procedures, growing global adoption of Focal One with 87 systems installed as of December 31, 2025, accelerating procedure and installation growth rates between 2021 and 2025, and preliminary 2025 HIFU revenue trends with 2026 guidance referenced from a prior earnings release.
EDAP TMS director David R. Horn filed an initial insider ownership report stating that he beneficially owns no securities of the company. The Form 3 identifies him as a director only, with no derivative or non-derivative holdings reported and notes a power of attorney appointment.
EDAP TMS S.A. reported changes to its Board of Directors. On February 10, 2026, director Glen French resigned from the Board and from the audit, compensation, and nominations committees, with the company stating his resignation was not due to any dispute or disagreement.
On February 11, 2026, David Horn was appointed to the Board to fill this vacancy and will serve on the audit and nominations committees. His appointment will be submitted to shareholders at the next annual Ordinary and Extraordinary General Meeting. EDAP highlights Mr. Horn’s senior leadership role at Seer, Inc. and his more than 20 years of healthcare investment banking experience at Morgan Stanley, as well as prior roles in medical devices and life sciences. The company issued a press release on February 12, 2026 detailing these board changes.
EDAP TMS SA senior vice president of marketing and product management, Steven Annen, filed an initial statement of beneficial ownership. He reports owning 41,490 shares of EDAP common stock, which includes restricted stock units granted under the company’s 2025 RSU (Free Share) Plan with vesting milestones through December 2027 and June 2028. He also holds stock options exercisable for 80,000 shares at $8.85 per share and 123,750 shares at $1.74 per share, with option vesting staggered monthly over multi‑year schedules.
EDAP TMS SA filed an initial ownership report for Chief Executive Officer and Director Rhodes Ryan. As of January 1, 2026, he beneficially owned 301,149 shares of EDAP common stock directly, including restricted stock units granted under the company’s 2025 RSU (Free Share) Plan. These RSUs each represent one share of common stock, with four-sixths vesting on the second anniversary of the June 20, 2025 grant date and the remaining two-sixths vesting in installments on December 20, 2027 and June 20, 2028.
He also directly holds several stock option awards over EDAP common stock: 800,000 options granted June 11, 2021 at an exercise price of $6.57, 200,000 options granted May 2, 2023 at $11.87, 100,000 options granted March 26, 2024 at $8.03, and 500,000 options granted April 15, 2025 at $1.42. These options become exercisable in tranches beginning six months after each grant date and then on a monthly basis through the third anniversary of the respective grants.
EDAP TMS SA director Lance Willsey filed an initial ownership report showing he beneficially owns 1,241,780 shares of Common Stock directly. He also holds stock options for 280,000 shares of Common Stock with an exercise price of $1.42 per share, converted from 1.21 euros using an exchange rate of EUR 1 to USD 1.1750.
The options were granted on April 15, 2025 and became exercisable as to one-sixth of the grant on the six-month anniversary of that date, with the remaining options becoming exercisable on a monthly basis through the third anniversary of the grant date.
EDAP TMS SA filed an initial ownership report showing that Chief Financial Officer Kenneth S. Mobeck beneficially owns 56,610 shares of common stock as of 01/01/2026, held directly. This amount includes restricted stock units granted under the company’s 2025 RSU (Free Share) Plan, where each RSU represents the right to receive one share of EDAP common stock with vesting stretching from the second anniversary of the June 20, 2025 grant date through June 20, 2028.
He also directly holds stock options covering 375,000 shares exercisable until 12/15/2032 at $11.68 per share, options on 100,000 shares expiring 01/18/2034 at $6.22 per share, and options on 165,000 shares expiring 06/20/2035 at $1.74 per share. The options vest in stages over several years based on specified schedules tied to each grant date.
EDAP TMS SA’s Chief Accounting Officer, Francois Mattieu Dietsch, filed an initial ownership report as of January 1, 2026. He beneficially owns 12,000 shares of common stock, held directly.
He also directly holds several grants of employee stock options over EDAP common stock, including options for 20,000 shares expiring April 26, 2026, 10,000 shares expiring April 25, 2027, and additional blocks of 10,000, 10,000, 7,500, and 15,000 shares with expirations ranging from August 29, 2028 through June 20, 2035. The filing footnotes explain that each option grant vests gradually starting six months after the grant date and that exercise prices were converted from euros into U.S. dollars using a stated exchange rate.
EDAP TMS S.A. filed a current report to note that it released a press release with select preliminary unaudited financial and operational results for the fourth quarter and full fiscal year ended December 31, 2025, along with select guidance for 2026. The press release is provided as Exhibit 99.1.
The company also prepared an investor Presentation for analysts and investors, furnished as Exhibit 99.2. The company states that the presentation information is summary in nature, should be read together with its other SEC filings and public announcements, and that the materials in Items 2.02 and 7.01 and Exhibits 99.1 and 99.2 are furnished rather than filed and therefore are not subject to certain Exchange Act and Securities Act liability provisions.
EDAP TMS SA director Schulz Fran filed an initial statement of beneficial ownership on Form 3. The filing reports beneficial ownership of 5,100 shares of common stock, held as direct ownership. The event date for this ownership report is January 1, 2026.
The form is filed for a single reporting person and is signed by Blandine Confort as attorney-in-fact under a power of attorney, indicating the director has authorized this representative to make SEC filings on their behalf.